Polymeric Biomaterials for Pharmaceuticals and Biomedical Application

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 2927

Special Issue Editor


E-Mail Website
Guest Editor
Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy
Interests: development and characterization of drug delivery systems (DDS) with particular attention to colloidal systems for drug targeting and delivery; polymeric biomaterials for applications in regenerative medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, key features of biopolymers such as their biodegradability, biocompatibility and low long-term toxicity have attracted a great deal of attention from researchers, and so many new polymeric systems have been developed for a wide range of applications.

Their use could be aimed, for example, at modulating the physicochemical characteristics of drugs (e.g., low solubility in water) as well as their biopharmaceutical properties (e.g., circulation time, elimination rate from the body) or pharmacological features, giving the possibility to overcome known drug-related side effects due to off-target actions or high doses of administration.

Another interesting application of biopolymers is in regenerative medicine. One example is in the realization of scaffolds with customizable shapes, which can allow the attachment, diffusion and growth of cells, thus allowing the repair of different tissues and avoiding the need to remove materials after their action due to intrinsic biodegradability.

The purpose of this Special Issue is to present innovative applications and advances of polymeric biomaterials for biomedical applications.

In particular, research works focused on innovative polymeric-biomaterials-based scaffolds which are potentially useful for applications in regenerative medicine and drug delivery will be appreciated, and special attention will be paid to works minimizing the impact of the production process on the environment by using ecological solvents and, as much as possible, green chemistry with simplified processes.

All researchers working in the field are cordially invited to contribute.

Dr. Delia Mandracchia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biopolymers-based scaffolds
  • tissue engineering
  • drug delivery and targeting
  • controlled drug release
  • green materials
  • eco-friendly materials

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

23 pages, 7832 KiB  
Article
Evaluation of Oromucosal Natural Gum-Based Emulgels as Novel Strategy for Photodynamic Therapy of Oral Premalignant Lesions
by Emilia Szymańska, Joanna Potaś, Marcin Baranowski, Robert Czarnomysy, Magdalena Ewa Sulewska, Anna Basa, Małgorzata Pietruska, Krzysztof Bielawski and Katarzyna Winnicka
Pharmaceutics 2023, 15(10), 2512; https://doi.org/10.3390/pharmaceutics15102512 - 23 Oct 2023
Cited by 1 | Viewed by 832
Abstract
Photodynamic therapy (PDT) recently has been shown as a promising option in the treatment of premalignant lesions of the soft oral tissues. Effective delivery of photosensitizer is challenging due to poor drug adherence to the oromucosal epithelium. In the present work, emulgels composed [...] Read more.
Photodynamic therapy (PDT) recently has been shown as a promising option in the treatment of premalignant lesions of the soft oral tissues. Effective delivery of photosensitizer is challenging due to poor drug adherence to the oromucosal epithelium. In the present work, emulgels composed of natural polysaccharide gums (tragacanth, xanthan and gellan) were evaluated as novel oromucosal platforms of delta-aminolevulinic acid (ALA) for PDT. Apart from mucoadhesive and textural analysis, the specific steps involved studies on drug penetration behavior and safety profile using a three-dimensional human oral epithelium model (HOE). All designed emulgels presented greater mucoadhesiveness when compared to commercial oromucosal gel. Incorporation of ALA affected textural properties of emulgels, and tragacanth/xanthan formulation with greater hardness and cohesiveness exhibited a protective function against the mechanical tongue stress. Permeability studies revealed that ALA is capable of penetrating across oromucosal epithelium by passive transport and all formulations promoted its absorption rate when compared to a commercial topical product with ALA. Importantly, the combination of tragacanth and xanthan profoundly enhanced photosensitizer retention in the buccal epithelium. Tested samples performed negligible reduction in cell viability and moderately low IL-1β release, confirming their non-irritancy and compatibility with HOE. Overall, the presented findings indicate that tragacanth/xanthan emulgel holds promise as an oromucosal ALA-carrier for PDT strategy. Full article
(This article belongs to the Special Issue Polymeric Biomaterials for Pharmaceuticals and Biomedical Application)
Show Figures

Figure 1

Review

Jump to: Research

32 pages, 3538 KiB  
Review
Biomaterial Drug Delivery Systems for Prominent Ocular Diseases
by Avin Sapowadia, Delaram Ghanbariamin, Libo Zhou, Qifa Zhou, Tannin Schmidt, Ali Tamayol and Yupeng Chen
Pharmaceutics 2023, 15(7), 1959; https://doi.org/10.3390/pharmaceutics15071959 - 15 Jul 2023
Cited by 5 | Viewed by 1848
Abstract
Ocular diseases, such as age-related macular degeneration (AMD) and glaucoma, have had a profound impact on millions of patients. In the past couple of decades, these diseases have been treated using conventional techniques but have also presented certain challenges and limitations that affect [...] Read more.
Ocular diseases, such as age-related macular degeneration (AMD) and glaucoma, have had a profound impact on millions of patients. In the past couple of decades, these diseases have been treated using conventional techniques but have also presented certain challenges and limitations that affect patient experience and outcomes. To address this, biomaterials have been used for ocular drug delivery, and a wide range of systems have been developed. This review will discuss some of the major classes and examples of biomaterials used for the treatment of prominent ocular diseases, including ocular implants (biodegradable and non-biodegradable), nanocarriers (hydrogels, liposomes, nanomicelles, DNA-inspired nanoparticles, and dendrimers), microneedles, and drug-loaded contact lenses. We will also discuss the advantages of these biomaterials over conventional approaches with support from the results of clinical trials that demonstrate their efficacy. Full article
(This article belongs to the Special Issue Polymeric Biomaterials for Pharmaceuticals and Biomedical Application)
Show Figures

Figure 1

Back to TopTop